Symbol="LVTX"
AssetType="Common Stock"
Name="LAVA Therapeutics NV"
Description="Lava Therapeutics BV, a biotechnology company, is dedicated to developing a portfolio of gamma-delta bispecific T-cell activators (gamma-delta bsTCE) for the treatment of solid tumors and hematologic malignancies based on its platform. The company is headquartered in Utrecht, the Netherlands."
CIK="1840748"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="YALELAAN 60, UTRECHT, NL"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="48634800"
EBITDA="-37133000"
PERatio="None"
PEGRatio="None"
BookValue="2.863"
DividendPerShare="0"
DividendYield="0"
EPS="-1.34"
RevenuePerShareTTM="0.752"
ProfitMargin="-1.839"
OperatingMarginTTM="-1.922"
ReturnOnAssetsTTM="-0.178"
ReturnOnEquityTTM="-0.392"
RevenueTTM="19593000"
GrossProfitTTM="-20714000"
DilutedEPSTTM="-1.34"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.198"
AnalystTargetPrice="7.2"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="5.81"
PriceToBookRatio="1.881"
EVToRevenue="4.935"
EVToEBITDA="-2.619"
Beta="-0.39"
num_52WeekHigh="7.38"
num_52WeekLow="1.365"
num_50DayMovingAverage="2.018"
num_200DayMovingAverage="3.003"
SharesOutstanding="26289100"
DividendDate="None"
ExDividendDate="None"
symbol="LVTX"
open="1.89"
high="1.95"
low="1.80"
price="1.85"
volume="71407.00"
latest_trading_day="2023-07-24"
previous_close="1.92"
change="-0.07"
change_percent="-3.6458%"
aroon_positive_momentum_days="35"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="35"
Volume_recent_avg="437458"
Change_recent_avg="-0.02"
Delta_recent_avg="0.16"
Variance_recent_avg="0.08"
Change_ratio_recent_avg="-1.42"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="35"
Aroon_momentum_negative="65"
image_negative_thumbnail_id_1="1126"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0159.jpeg"
image_negative_thumbnail_id_2="1156"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0190.jpeg"
image_neutral_thumbnail_id_1="569"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0030.jpeg"
image_neutral_thumbnail_id_2="539"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0060.jpeg"
image_positive_thumbnail_id_1="983"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0145.jpeg"
image_positive_thumbnail_id_2="1013"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0175.jpeg"
image_professor_thumbnail_id_1="1193"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0027.jpeg"
image_professor_thumbnail_id_2="1174"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
